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httpCarotid endarterectomy for symptomatic low-grade
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Antonio Toniato, MD,a and Claudio Baracchini, MD,c Padova, Italy
Objective: Although the management of carotid disease is well established for symptomatic lesions $70%, the surgical
treatment for a symptomatic #50% stenosis is not supported by data from randomized trials. Factors other than lumen
narrowing, such as plaque instability, seem to be involved in cerebral and retinal ischemic events. This study analyzes the
early-term and long-term outcomes of carotid endarterectomy (CEA) performed in patients with low-grade (#50% on
North American Symptomatic Carotid Endarterectomy Trial criteria) symptomatic carotid stenosis.
Methods: The study involves 57 consecutive patients undergoing CEA for symptomatic low-grade carotid disease at our
institution over 5 years, and 21 (36.8%) had experienced more than one ischemic event. Overall, 48 (84.2%) had a minor
stroke, and nine (15.8%) had an episode of retinal ischemia. Diagnosis was made by a vascular neurologist based on an
ultrasound examination combined with noninvasive imaging studies, after ruling out other possible causes of emboli-
zation. Before CEA, all patients were receiving antiplatelet treatment, and 87% were taking statins. All patients underwent
eversion CEA under general deep anesthesia, with selective shunting. All carotid plaques were examined histologically.
Long-term follow-up (median, 28 months; mean, 32 6 5 months; range, 3-56 months) was obtained for 55 patients.
Results: No 30-day strokes or deaths occurred, and no patients had recurrent neurologic events related to the revascu-
larized hemisphere during the follow-up. No late carotid occlusions were detected, but one asymptomatic moderate
restenosis was documented. There were seven late deaths (12.7%), none of which were stroke-related. Survival rates were
98% at 1 year and 90% at 3 years. All removed carotid plaques showed different features of ulceration or rupture, with
underlying hemorrhage associated with a thrombus.
Conclusions: This study shows that CEA is a safe, effective, and durable treatment for patients with symptomatic low-
grade carotid stenosis associated with unstable plaque. Patients had excellent protection against further ischemic
events and survived long enough to justify the initial surgical risk. Plaque instability seems to play a major part in the
onset of ischemic events, regardless the entity of lumen narrowing. (J Vasc Surg 2014;59:25-31.)Carotid disease accounts for 10% to 20% of all ischemic
strokes,1,2 and generally speaking, the pathogenetic sub-
strate of stroke attributable to carotid pathology is a plaque
that causes hemodynamic turbulences ascribable to area
reduction and with a complicated structure and surface
generating emboli or determining occlusion. Guidelines
for the best management of symptomatic internal carotid
artery stenosis are based mainly on the conclusions of large
randomized clinical trials (RCTs) such as the North Amer-
ican Symptomatic Carotid Endarterectomy Trial (NAS-
CET)3 and the European Carotid Surgery Trial (ECST).4
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://dx.doi.org/10.1016/j.jvs.2013.06.079endarterectomy (CEA), compared with best medical
management, is highly beneﬁcial for individuals with cere-
brovascular symptoms attributable to a carotid luminal nar-
rowing $69% on angiography, with a 16% lower 5-year
absolute risk of ipsilateral ischemic stroke. For symptomatic
patients with moderate (50%-69%) carotid stenosis, the risk
reduction is only 4.6%, and the beneﬁt of CEA is minimal
for symptomatic patients with mild (30%-49%) carotid
stenosis.5
There is a consensus that medical therapy is as efﬁcient
as surgery for symptomatic patients with #50% carotid
stenosis, but the presence of a vulnerable plaque, conﬁrmed
by well-established ultrasound criteria, might place these
patients at a higher risk of cerebral ischemic events recur-
rence. As determined from results of RCTs, surgery does
little to reduce the risk of ipsilateral ischemic stroke for
low-grade (#50%) symptomatic stenosis, not because
patients are risk-free but because the surgical risk exceeds
the stroke risk with medical management. Stroke risk and
the beneﬁts of CEA both increase with higher degrees of
stenosis; thus, carotid narrowing is nowadays the most vali-
dated stroke risk parameter on which management deci-
sions are based.6
The optimal approach for managing lower degrees of
carotid disease remains unclear, however.7 Several studies
have shown that severe stenotic lesions might remain
asymptomatic for many years on best medical treatment,825
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to a cerebral ischemic event over a short period of time due
to plaque complication.9-11
In the last few years, progressive improvement has
occurred in ultrasound B-mode imaging and in ultrasound
contrast agents, and ultrasound B-mode is presently the
best method for demonstrating low-grade carotid stenosis.12
Although velocity measurements rule out a more severe
stenosis, B-mode imaging in the longitudinal and cross-
sectional planes is more relevant than velocity values in
low-grade disease. Furthermore, the measurement of area
reduction is more accurate than diameter reduction, espe-
cially when confronted with plaques with an irregular
surface.13,14
In recent years, there has been a growing interest in
multiparameter carotid plaque assessment, placing less
emphasis on the degree of stenosis and more on its
morphology, mobility, and composition. Intraplaque
hemorrhage (IPH) and thin, ulcerated, or ruptured ﬁbrous
caps seem to be associated with higher stroke risk,15-20 sup-
porting the hypothesis, as in coronary artery disease, that
many cerebral infarctions result from distal emboliza-
tion,21-23 not hypoperfusion, as it occurs distally to severe
lesions or occlusions.24,25
This study was conducted to prospectively analyze the
early-term and long-term outcomes of CEA performed
outside the current guidelines in symptomatic patients
with low-grade carotid lesions, assessing the morphologic
and histologic features of the removed carotid plaques.
METHODS
The University of Padua, School of Medicine Ethics
Committee approved the study. All patients gave their
written informed consent to analyzing their records and
publishing the ﬁndings.
Patients. A prospectively compiled computerized
database was queried concerning all patients undergoing
CEA at our tertiary referral center between January 2008
and December 2012 for recently symptomatic (<2
months) carotid plaque causing a #50% stenosis according
to the NASCET criteria.3 All patients were already
receiving antiplatelet treatment, and most were taking
statins before they were enrolled.
After their ﬁrst ever ipsilateral or recurrent cerebral
ischemic event, or plaque progression/instability, they
entered the study and underwent CEA. Patients were
routinely monitored for the ﬁrst 3 days of their hospital
stay. They underwent transthoracic and transesophageal
echocardiography and were ﬁnally examined by a consultant
cardiologist to rule out any cardiac source of embolization.
A vascular neurologist attributed all cerebral or retinal
ischemic events to embolization from an ipsilateral carotid
stenosis. All patients were diagnosed with symptomatic
carotid lesions#50% based on velocity criteria (peak systolic
velocity <125 cm/s) on preoperative duplex ultrasound
performed by two experienced neurosonographers.26
Carotid plaque morphology and characteristics were
analyzed using contrast-enhanced carotid ultrasonography.Plaque morphology in terms of echogenicity, deﬁned with
reference to the sternocleidomastoid muscle, was assessed
in a modiﬁed version of the classiﬁcation proposed by
Gray-Weale et al27 and graded from 1 to 4 as echolucent,
predominantly echolucent, predominantly echogenic, or
echogenic.19 Unstable plaque was deﬁned on carotid ultra-
sound as echolucent or heterogeneous plaque, with sur-
face irregularities, ulcer, or rupture. Plaque inﬂammation,
adventitial vasa vasorum, intimal angiogenesis, and plaque
neovascularization were identiﬁed on contrast-enhanced
carotid ultrasonography as potential indicators of atheroma
instability.
All patients underwent additional noninvasive imag-
ing,28 including magnetic resonance imaging (MRI)/
angiography, computed tomography angiography, or
digital subtraction angiography, to exclude tandem lesions
(ie, a second intracranial lesion on the same vessel) and
to conﬁrm the decision to perform CEA. Transcranial
color-coded Doppler sonography was also performed in
all patients to assess vasomotor reactivity and any intracra-
nial atherosclerotic lesions or intracranial compensatory
collaterals.
The patients’ demographic and clinical data were
recorded on a standardized form, including potential
atherosclerotic risk factors, several risk-related charac-
teristics, such as cholesterol, high-density lipoprotein
cholesterol, triglycerides, or homocysteine, anatomic and
clinical variables, preoperative medication, details of
surgery, and all perioperative outcomes. The consultant
neurologist assessed all patients preoperatively, on waking
from the anesthesia, before discharge from the hospital,
and during the follow-up. All patients with diabetes or
hyperlipidemia, or both, and those with prior ischemic
events were receiving statin therapy.
Surgical procedure. All surgical procedures were
eversion CEAs performed by the same surgeon, with
patients under general anesthesia, and routine intraopera-
tive electroencephalographic monitoring was used for
selective intraluminal shunting. The technical details of
the surgical procedure have been described elsewhere.29
Shunting depended exclusively on electroencephalo-
graphic changes consistent with cerebral ischemia occur-
ring during carotid cross-clamping and unrelated to any
bradycardia or arterial hypotension. Patients were
administered intravenous unfractionated heparin (5000
U) before carotid clamping. Heparinization was never
reversed with protamine up until December 2009; from
January 2010 onward, all patients had partial (half-dose)
heparin reversal. No completion angioscopy or imaging
studies were performed.
Patients were usually monitored in the recovery room
for 2 hours until their blood pressure and neurologic status
were judged acceptable and then were transferred to
a nursing unit specialized in vascular care for 12 to
24 hours. Patients with severe headache were closely moni-
tored for hyperperfusion syndrome, and hypertension was
treated aggressively. Most patients were discharged 48 to
72 hours after CEA.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 1 Ballotta et al 27Histopathologic analysis. All everted plaques were
removed en block, with no longitudinal incision (to elimi-
nate the potential for artifact), and immediately ﬁxed in
formalin. The plaque was cut transversally to the longitu-
dinal lumen into 5-mm sections for embedding in
parafﬁn. Four adjacent 5- to 10-mm thick sections were
taken from each block and stained/immunostained with
(1) hematoxylin and eosin, (2) elastin van Gieson to assess
the ﬁbroelastic component, (3) CD68 antibody for
macrophages, and (4) CD3 antibody for lymphocytes.
Histologic features. For each plaque, the following
features were considered:
1. Ulceration of the ﬁbrous cap in a setting of endothe-
lial cells disruption;
2. Plaque rupture in a setting of disruption or complete
clear communication between the lipid core and the
lumen, usually at a point of ﬁbrous cup thinning or
inﬂammation, or both;
3. Lipid core size, deﬁned as the area of amorphous
material containing cholesterol crystals out of the
total area of the plaque;
4. Calciﬁcationdjudged to be in large amounts when
nodular deposits were seen (nodular calciﬁcation)
or in small amounts when there was only stipplingd
and its location within the plaque;
5. Neovascularization, when small vessels or capillaries
were identiﬁed mostly within loose extracellular
matrix;
6. Type and location of inﬂammatory cell inﬁltrate
within the plaque;
7. Percentage of ﬁbrous tissue out of the total area of
plaque;
8. IPH, including recent or earlier hemorrhage, deﬁned
as evidence of erythrocytes or erythrocyte debris in
the plaque disrupting its architecture; and
9. Mural or occlusive thrombus, recorded in the setting
of nonocclusive or occlusive thrombus in the lumen,
characterized by platelets, ﬁbrin strands, and white
and red blood cells.
The type of atherosclerotic plaque was recorded
according to the American Heart Association/Virmani
classiﬁcation.30
Surveillance protocol. After discharge, nurses moni-
tored the patients’ vital parameters. The consultant neurolo-
gist systematically performed a physical and neurological
assessment of all surviving patients. Post-CEA duplex ultra-
sound scans were performed by two experienced neuro-
sonographers at 1, 6, and 12 months, and then yearly,
assessing any carotid restenosis or late occlusions. Neurologic
events were always classiﬁed by the consultant neurologist as:
d Transient ischemic attacks (TIAs), deﬁned as tempo-
rary hemispheric symptoms lasting #24 hours, with
complete recovery;
d Amaurosis fugax, noted as transient monocular visual
loss;d Minor stroke, a clinical syndrome of rapidly developing
signs or symptoms of focal loss of cerebral function of
vascular origin lasting >24 hours but not leading to
any handicap or signiﬁcant impairment in activities of
daily living, assessed as <3 on the modiﬁed Rankin-
scale31; or
d Major stroke, deﬁned as a focal neurologic deﬁcit
lasting >30 days and inducing a change in lifestyle,
assessed as 3/5 on the modiﬁed Rankin scale.
Brain imaging (computed tomography or MRI) was
performed in all patients with new neurologic deﬁcits after
CEA. Cardiac complications were classiﬁed by the same
cardiologist and included (1) myocardial infarction diag-
nosed from creatinine kinase-MB levels and electrocardio-
gram ﬁndings, (2) pulmonary edema conﬁrmed by chest
X ray imaging, (3) documented ventricular ﬁbrillation or
primary cardiac arrest, and (4) new congestive heart failure,
requiring a pacemaker. A postoperative electrocardiogram
was obtained routinely in all patients with a history of coro-
nary artery disease, congestive heart failure, or arrhythmia
(rhythm other than sinus), and cardiac isoenzymes were
tested in all patients with new ﬁndings on the postopera-
tive electrocardiogram. Other complications and events
observed during the follow-up were recorded in accor-
dance with the guidelines of the Ad Hoc Committee on
Reporting Standards for Cerebrovascular Disease, Society
for Vascular Surgery/North American Chapter of the
International Society of Cardiovascular Surgery.32
End points were perioperative stroke and death, nonre-
currence or relief of hemispheric symptoms, carotid reste-
noses or late occlusions, and stroke-free survival rates.
Statistical analysis. The statistical analysis was per-
formed with SSPS 12.0.1 software (SPSS Inc, Chicago,
Ill). The patients’ demographic data are given as medians,
means and ranges, and baseline clinical and diagnostic ﬁnd-
ings as incidence rates. Survival rates were calculated with
the Kaplan-Meier method and reported as life-table anal-
yses. Signiﬁcance was assumed at P < .05.
RESULTS
During the study period, 369 CEAs were performed at
our institution in 321 patients for symptomatic and asymp-
tomatic carotid lesions based on the NASCET3 and the
Asymptomatic Carotid Atherosclerosis Study (ACAS)33
recommendations. An additional 57 patients had 57
CEAs for symptomatic #50% carotid stenoses and formed
our study population. None of the CEA procedures
considered here were aborted or incomplete, and none of
the patients were refused CEA for technical reasons
emerging during the surgery. The preoperative characteris-
tics of the patients are summarized in Table I.
Before CEA, 3 patients had experienced 4 ischemic
events, 7 patients 3 events, 11 patients 2 events, and the
other 36 patients only 1 event. The event prompting
CEA or, for patients with multiple events their last ischemic
event was a minor ischemic stroke in 48 patients and
a retinal ischemia in nine. At the time of their ischemic
Table II. Selected risk-related variables stratiﬁed by
plaque echogenicity
Variablea
Echolucent
(n ¼ 16)
Predominantly
echolucent
(n ¼ 41)
Cholesterol, mmol/L 7.45 6 1.23 7.34 6 1.32
HDL cholesterol, mmol/L 1.37 6 0.35 1.38 6 0.40
Triglycerides, mmol/L 2.06 6 1.12 2.09 6 1.09
Homocysteine, mmol/L 11.5 (7.8-40.7) 11.6 (8.3-41.8)
HDL, High-density lipoprotein.
aValues are presented as unadjusted means 6 standard deviation or median
(range).
Table III. Plaque features stratiﬁed by clinical
presentation
Variable
Stroke
(n ¼ 48),
Retinal ischemia
(n ¼ 9),
Total
(N ¼ 57),
No. (%) No. (%) No. (%)
Type of plaque
Fibrous 15 (31.2) 2 (22.2) 17 (29.8)
Atheromatous 33 (68.8) 7 (77.8) 40 (70.2)
Thrombotic active
plaque
48 (100) 9 (100) 57 (100)
Fibrous cap
Rupture 33 (68.8) 7 (77.8) 40 (70.2)
Ulceration 15 (31.2) 2 (22.2) 17 (29.8)
IPH 41 (85.4) 8 (88.9) 49 (86)
Thrombus
Mural 27 (56.2) 3 (33.3) 30 (52.6)
Occlusive 20 (41.7) 5 (55.6) 25 (43.8)
Calciﬁcation
Nodular 32 (66.7) 6 (66.6) 38 (66.7)
Mild 12 (25) 2 (22.2) 14 (24.6)
Neovascularization 21 (43.7) 5 (55.6) 26 (45.6)
IPH, Intraplaque hemorrhage.
Table I. Patient demographics, risk factors, clinical
presentation, time of surgery from the last ischemic event,
and preoperative medical treatment
Variables No. (%) or mean 6 SD
Preoperative characteristics
Patients/surgical procedures 57 (100)
Male gender 38 (66.7)
Age, years 74.6 6 2.8
<70 10 (17.5)
70-80 41 (71.9)
>80 6 (10.5)
Risk factors
Hypertension 38 (66.7)
Smoking 42 (73.6)
Diabetes 19 (33.3)
Hyperlipidemia 30 (52.6)
Cardiac disease 20 (36.8)
Chronic kidney disease 3 (5.2)
Pulmonary disease 7 (12.3)
Peripheral atherosclerotic disease 32 (56.1)
Symptoms
Stroke 48 (84.2)
Retinal ischemia 9 (15.8)
Time of CEA from the last ischemic
event, weeks
2 42 (3.7)
3 8 (14.0)
4 3 (5.3)
8 4 (7.0)
Preoperative medications
Antithrombotic therapy 57 (100)
Aspirin 20 (36.8)
Ticlopidine 9 (15.8)
Aspirin and clopidogrel 17 (29.8)
Clopidogrel 8 (14.0)
Warfarin 3 (5.3)
Statin therapy 49 (86.0)
CEA, Carotid endarterectomy; SD, standard deviation.
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mic events), all patients were taking antiplatelet drugs
or antithrombotic therapy (20 aspirin, 9 ticlopidine, 17
aspirin and clopidogrel, 8 clopidogrel only, and 3 warfarin
due to prior atrial ﬁbrillation) and 49 (86%; all patients
who had 1 ischemic event, 6 who had 3 events, 6 who
had 2 events, and 1 who had 4 events) were also taking sta-
tins. CEA was performed in 42 patients within 2 weeks of
their (last) ischemic event, in 8 within 3 weeks, in 3 within
1 month, and in the remaining 4 within 2 months
(Table I). Some risk-related characteristics stratiﬁed by pla-
que echogenicity are reported in Table II.
Perioperative (30-day) results. No perioperative
strokes, deaths, or cerebral hemorrhages occurred in this
series. One transient neurologic deﬁcit (1.7%) ipsilateral
to the revascularized hemisphere resolved #24 hours
postoperatively in a patient with a contralateral carotid
occlusion. Two minor complications (3.5%) occurred:
one patient had neck bleeding not requiring surgical evac-
uation, and one had a temporary hypoglossal nerve injury
that completely recovered spontaneously #30 days.Histologic analysis revealed various features of ulcera-
tion or rupture of the atherosclerotic plaques with under-
lying IPH associated with a fresh thrombus, conﬁrming
preoperative ultrasound ﬁndings and MRI images evoca-
tive of unstable plaque (Table III).7
Long-term outcomes. Long-term follow-up was ob-
tained in all but two patients (median, 28 months; mean,
32 6 5 months; range, 3-56 months). No patients had any
recurrent neurologic event relating to the revascularized
hemisphere.
No late carotid occlusions were detected in this series.
One moderate restenosis (between 50% and 70%) without
symptoms was identiﬁed #24 months after CEA, which
remained stable at subsequent duplex ultrasound scans
and was treated conservatively.
Seven late deaths (12.7%) occurred, none of them
stroke-related, at a mean of 30 months after CEA: four
patients died of myocardial infarction (none had coronary
artery disease at the time of CEA or perioperative cardiac
events), two of malignancy, and one after a car accident.
Kaplan-Maier life-table analysis showed that the survival
JOURNAL OF VASCULAR SURGERY
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1.978) at 1 year, with 45 patients at risk, and 90.2%6 4.4%
(95% conﬁdence interval, 3.838-5.157) at 3 years, with 22
patients at risk.
DISCUSSION
The present study shows that patients with low-grade
carotid stenosis may develop medically refractory ischemic
events in the presence of unstable plaque, identiﬁable using
noninvasive diagnostic tools, and that CEA is a safe, effec-
tive, and durable procedure in such cases. No major
ischemic events or deaths occurred perioperatively, and
no patients had recurrent cerebrovascular events related
to the revascularized hemisphere or died of stroke during
the follow-up. No late carotid occlusions were detected,
and a moderate restenosis was only identiﬁed in 1.8% of
the endarterectomized vessels. On the basis of current
guidelines, which focus mainly on the severity of carotid
lumen narrowing, surgical management would not be rec-
ommended in such symptomatic patients due to the
minimal balance between beneﬁts and risks of CEA.3-5
Low-grade carotid lesions are often disregarded as
potential causes of cerebral embolization because of
presumed coexisting diseases (eg, atrial ﬁbrillation) and
because the size of the plaque may be underestimated as
a consequence of vascular remodelling.7 Evaluating the
stroke risk by the degree of stenosis alone may not sufﬁce;
additional parameters are needed to better identify
subgroups of high-risk patients who would beneﬁt more
from surgery.7,28,34 Plaque morphology, regardless of
lumen narrowing, seems to inﬂuence the likelihood of
adverse ischemic events as well as being a valid predictor
of ipsilateral stroke, the unstable plaque being an intriguing
entity that has been inconclusively studied with contradic-
tory results.15-20
Ultrasound evaluation combined with noninvasive
cerebral imaging studies has proved valuable for character-
izing plaque and assessing stroke risk.19,35-37 All of our
patients’ low-grade carotid plaques showed signs of insta-
bility: histology revealed a ruptured or ulcerated ﬁbrous
cap with underlying IPH, associated with a fresh thrombus
within the lumen. Similar ﬁndings were recently reported
in 127 patients with unstable plaque who underwent
CEA38: acute thrombotic plaques were signiﬁcantly more
associated with stroke than with TIA or asymptomatic indi-
viduals and involved more ulcerated (73%) than ruptured
plaques (27%).39 These lesions occurred mainly in carotid
segments with nonsigniﬁcant stenosis (#50%), whereas
healed lesions prevailed in segments with >70% luminal
narrowing.38
The ﬁnding that rupture occurs more frequently in
lower grades of stenosis is not new7,39 and is consistent
with Laplace’s law, which states that more pressure is
exerted on the ﬁbrous cap of a nonsigniﬁcant lesion than
on severe stenotic plaques.23 In a landmark article on the
role of carotid plaque rupture and thrombosis in the path-
ogenesis of ischemic stroke in patients who underwent
CEA for symptomatic and asymptomatic severe carotidlesion, Spagnoli et al20 found a fresh thrombus at the site
of the ruptured cap in all plaques removed #2 months of
symptoms onset, whereas different stages of organized
thrombosis were seen in plaques removed 3 to 22 months
after the event, suggesting that thrombosis of the ruptured
plaque plays a fundamental part in the pathogenesis of
cerebral symptoms, probably due to artery-to-artery micro-
embolism arising from the thrombotic lesion.
About one-third of our patients had more than one
ischemic event before CEA. This correlates well with
the demonstration that the initiating ischemic event
involves rupture of the plaque, which then remains
unstable for up to 2 years20 and susceptible to further
superﬁcial cap erosion or rupture and thrombosis, predis-
posing patients to a continuous release of emboli in the
distal cerebral territory.20 Salem et al40 conﬁrmed as
much by showing that plaques excised from patients
within 1 to 2 weeks of their last clinical event had more
unstable features, which diminished with time (over
3 weeks), then increased again. None of our patients
had ischemic events during their follow-up, which under-
scores the signiﬁcant role of unstable plaque, whatever its
extent, in the pathogenesis of ischemic cerebral events.
Our ﬁndings coincide with those of a retrospective study
of 31 patients with symptomatic #70% carotid stenosis
on noninvasive imaging but who nonetheless underwent
CEA: macroscopically, all removed plaques revealed pla-
que rupture with IPH, and none of the patients had
further ischemic events after CEA.28
As in other studies,40 we offered CEA to patients
refractory to multidisciplinary medical treatment, including
patients with cerebral/retinal ischemia or carotid plaque
progression, regardless of aggressive risk-factor control
plus full antithrombotic treatment, plus high-dose statin
therapy. All patients received antiplatelet or anticoagulant
treatment before surgery and had IPH underlying discon-
tinuous or ruptured ﬁbrous cap. It is not clear whether
antithrombotics might have exacerbated bleeding into
the plaque, thereby hastening cap erosion or rupture and
acute thrombus formation, and this matter would warrant
further investigation.
Our ﬁndings should be interpreted bearing the study’s
limitations in mind. First, although the analysis was
prospective, the sample was relatively small and concerned
a single institution and the same surgeon.
Second, the similar features seen in the carotid plaques
may stem from the fact that all patients underwent surgery
relatively soon after their ischemic event as a result of
efforts to expedite CEA for symptomatic patients whenever
possible.
Third, we agree that microembolic signal detection by
transcranial Doppler is a surrogate marker of carotid plaque
activity and progression of the lesion and is positively asso-
ciated with a greater embolic potential of the plaque and
a higher stroke recurrence rate. It is a very long procedure,
however, needing multiprobe monitoring. The most accu-
rate technique requires an experimental carotid microem-
bolic signal detector, which we do not have.
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ison with outcomes in patients with symptomatic low-
grade stenosis followed up with the best medical treatment
instead of CEA, but it seemed unethical to keep patients on
medication if CEA was indicated.
Finally, we are aware that the absence of perioperative
and late major or minor neurologic complications or
stroke-related deaths among our patients might denote
relative lack of power, limiting the reliability of the results.
CONCLUSIONS
This prospective study showed that CEA is a safe, effec-
tive, and durable option for treatment of patients with
symptomatic carotid low-grade stenosis associated with
unstable plaque. Patients had excellent protection against
further ischemic events and survived long enough to justify
the initial surgical risk. Plaque instability seems to play
a major part in the occurrence of ischemic events, irrespec-
tive of lumen narrowing.
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